Dihexa

Dihexa is a small synthetic peptide derived from angiotensin IV, a fragment of the renin–angiotensin system. It was developed in academic research as part of efforts to design compounds that might support learning and memory, and it has attracted attention for showing potent effects on synapse formation in preclinical models.

Dihexa is investigational and remains at the animal-research stage. It is not an approved medicine for cognitive impairment, neurodegenerative disease, or any other indication, and the striking preclinical findings have not been translated into established human treatments.

The proposed mechanism for dihexa is based on preclinical work and centers on growth-factor signaling in the brain:

• Interacting with the hepatocyte growth factor (HGF) and its receptor c-Met, a pathway implicated in synapse formation
• Promoting synaptogenesis — the formation of new connections between neurons — in laboratory models
• Being designed for improved metabolic stability and brain penetration relative to its angiotensin IV parent

How these mechanistic observations translate into meaningful, durable cognitive outcomes in humans is unknown, and enhancing a growth-factor pathway also raises questions that preclinical models cannot fully answer.

Dihexa is not an approved medicine for cognition, dementia, or any condition in any major jurisdiction. It appears in research settings and in some experimental or nootropic-oriented product listings, where marketing claims typically far outpace the underlying, animal-stage evidence.

Because regulatory status, product quality, and evidence strength all vary, any consideration of dihexa should be grounded in local regulations and a clear understanding that it is an exploratory research compound rather than a validated cognitive therapy.

As a compound that is not approved for human therapeutic use, dihexa falls within WADA category S0 (Unapproved Substances), which covers substances not currently addressed by other sections of the Prohibited List and lacking approval for human use. On that basis it should be treated as prohibited at all times.

Athletes should confirm current status directly with their sport's governing body and the latest WADA list, since the classification of novel compounds can evolve.

Because dihexa has not undergone formal human safety evaluation, its side-effect profile in people is unknown. A notable theoretical concern is that it acts on a growth-factor pathway (HGF/c-Met) that is involved in cell growth and is studied in cancer biology, so the long-term implications of stimulating it deserve particular caution.

As with other experimental peptides, product sourcing, purity, and individual risk factors matter, and the absence of human data means high-level summaries cannot substitute for rigorous safety evaluation that has not yet been done.

Dihexa was engineered from angiotensin IV with the goal of greater stability and central nervous system access, and it is described in the literature as highly potent in preclinical models.

This section is conceptual only. It summarizes considerations discussed for investigational compounds and does not constitute medical advice.

Dihexa is chemically unusual for something sold as a peptide, and the details matter for how it is handled and marketed. Its full name is N-hexanoic-Tyr-Ile-(6)aminohexanoic amide: a two-residue core (tyrosine and isoleucine, taken from the Nle-Tyr-Ile fragment of norleucine¹-angiotensin IV) capped at the N-terminus with a hexanoic acid chain and at the C-terminus with an aminohexanoic amide. Those caps were added deliberately to increase hydrophobicity, reduce hydrogen bonding, and make the molecule orally active and blood-brain-barrier permeant (McCoy et al., J. Pharmacol. Exp. Ther., 2013).

Two consequences follow. First, the design goal was oral activity, so the injectable framing common in vendor listings is not what the compound was built for. Second, the modifications make dihexa lipophilic rather than a water-soluble peptide, so ordinary peptide reconstitution logic does not automatically apply — and no published pharmaceutical formulation of dihexa exists to consult.

Dihexa is frequently marketed alongside racetams, cholinergics, and other nootropic-category compounds. There is no published study of dihexa in combination with anything, in any species.

Research on dihexa has focused on preclinical models, where it has been reported as a potent promoter of synaptogenesis and as improving performance on memory-related tasks in animals. These findings generated substantial interest in it as a candidate for cognitive research.

However, the evidence base is almost entirely animal-stage, and preclinical promise frequently does not translate to humans. Claims about dihexa's cognitive benefits in people are not supported by controlled human trials and should be interpreted with strong caution.

For deeper dives on this compound, see:

• Dihexa areas of research interest
• Dihexa side effects and safety context
• Dihexa dosing concepts (educational)
• Dihexa research and evidence overview

How does dihexa relate to angiotensin IV? Angiotensin IV is a six-amino-acid fragment of the renin-angiotensin system that had been recognized for decades as procognitive in animals but was useless as a drug candidate: it was degraded quickly and crossed neither the gut nor the blood-brain barrier. Researchers at Washington State University narrowed the active region to a three-residue core (Nle-Tyr-Ile) and then chemically capped it, producing an orally active, brain-penetrant analog they named dihexa (McCoy et al., J. Pharmacol. Exp. Ther., 2013).

What is the HGF/c-Met pathway, and why does it invite caution? Hepatocyte growth factor binds c-Met, a receptor tyrosine kinase that drives cell growth, motility, and — in the brain — synapse formation. Dihexa's proposed mechanism was that it binds HGF and potentiates c-Met signaling, producing spinogenesis and synaptogenesis. The caution is that c-Met is one of the best-characterized oncogenic drivers in cancer biology, and an entire class of cancer drugs exists to inhibit it. A compound designed to push that pathway in the opposite direction, with no human safety data, sits in a category where the theoretical concern is specific rather than generic.

Has the dihexa research held up? This is the most important thing on this page, and it is rarely mentioned in write-ups of the compound. In April 2025 the Journal of Pharmacology and Experimental Therapeutics retracted two foundational papers from the originating laboratory: the 2014 study establishing that the procognitive and synaptogenic effects of angiotensin IV-derived peptides depend on HGF/c-Met activation (retraction notice, PMID 40312093), and the 2012 paper describing the development of angiotensin IV analogs as HGF/Met modifiers (retraction notice, PMID 40312092). The 2013 paper that first characterized dihexa itself carries an expression of concern issued by the same journal in 2021 (PubMed record). The mechanism most commonly cited for dihexa is therefore drawn from retracted literature.

Is dihexa really "10 million times more potent than BDNF"? That number comes from a 2012 Washington State University press release describing the lab's in-vitro assay of new neuronal connections, where dihexa was reported as seven orders of magnitude more powerful than brain-derived neurotrophic factor (WSU News, 2012). It was never a clinical comparison. It is a ratio of concentrations needed to produce an effect in cultured cells, from the same research program whose central papers have since been retracted or flagged — and BDNF itself has never been successfully developed as a therapeutic, so the comparator is not a benchmark of clinical benefit either.

Has dihexa been tested in humans? No. No study of dihexa is registered on ClinicalTrials.gov (searched August 2026), and no human safety, pharmacokinetic, or efficacy data have been published. There is no established dose, no monitoring framework, and no characterization of what chronic HGF/c-Met stimulation does in a person.